FindTrial
Sign In

The study of safety and immunogenicity of COVID-19 inactivated vaccine in patients with chronic hepatitis B virus infection

The study of safety and immunogenicity of COVID-19 inactivated vaccine in patients with chronic hepatitis B virus infection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048840
Enrollment
Unknown
Registered
2021-07-18
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B virus infection

Interventions

Convalescent stage of COVID-19 group:Nil
Healthy people vaccination group:Nil
Chronic liver disease group:Nil

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Chronic hepatitis B patients who are pre-vaccinated or have completed the first or second dose of COVID-19 inactivated vaccines; 2. Aged from 18 to 90 years.

Exclusion criteria

Exclusion criteria: 1. Cold, tooth extraction, tonsillitis and other conditions in the past 1 week; 2. Patients with other autoimmune diseases who are taking hormones and immunosuppressive drugs; 3. Patients with severe underlying diseases.

Design outcomes

Primary

MeasureTime frame
SARS-CoV-2 specific antibodies detection;—

Secondary

MeasureTime frame
SARS-CoV-2 specific T cell response;—

Countries

China

Contacts

Public ContactZheng Xin

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

xin11@hotmail.com+86 18602724981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026